Clinical Trial Update: CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy study of CAB-AXL-ADC in adults with non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CAB-AXL-ADC

Snippet

Sponsor: BioAtla, Inc. | Conditions: Non-Small-Cell Lung Cancer | Phase 2 | Status: COMPLETED